Samsung-Verily Partnership: Strategic Integration of Wearable Biometrics and AI Native Precision Health Platforms
- Nelson Advisors
- 1 hour ago
- 13 min read
The announcement on March 9th, 2026, at the HIMSS26 conference in Dallas, Texas, regarding the strategic partnership between Samsung Electronics America and Verily Life Sciences represents a definitive shift in the landscape of clinical research and population health management. By systematically bridging Samsung’s Galaxy Watch8 hardware with Verily’s Pre platform, the collaboration aims to replace the traditional, episodic model of clinical data collection with a continuous, longitudinal and multimodal evidence-generation engine.
This integration is not merely a technical linkage of devices and databases; it is a structural realignment designed to address the "data silo" problem that has historically plagued decentralised clinical trials and real-world evidence (RWE) initiatives. The partnership targets two primary customer segments, life sciences organisations and government agencies—offering them a bundled solution to monitor real-world populations with clinical-grade accuracy while leveraging advanced AI for workflow orchestration and predictive analytics.
The Galaxy Watch8 Ecosystem: Hardware as a Clinical Research Instrument
The Samsung Galaxy Watch8 serves as the primary data acquisition layer for this partnership, evolving from a consumer-centric wearable into a robust tool for clinical evidence generation. This transition is underpinned by a significant reengineering of the device’s internal architecture and sensor suite, designed to maximise both the accuracy and the continuity of physiological monitoring.
Advanced Sensor Architecture and the BioActive Module
At the core of the Galaxy Watch8’s capabilities is the upgraded Samsung BioActive Sensor, an integrated module that unifies three critical physiological sensors into a single package to ensure consistent skin contact and high-fidelity data capture.
The mechanical design of the watch was optimised to improve component mounting by 30%, resulting in an 11% thinner profile that enhances the stability of the sensor on the wrist. This stability is essential for reducing motion artifacts, which frequently degrade the quality of photoplethysmography (PPG) and bioelectrical impedance analysis (BIA) signals during active periods or sleep.
Hardware Component | Functional Specification | Clinical/Research Relevance |
Samsung BioActive Sensor | Integrates Optical Bio-signal, Electrical Heart, and BIA sensors. | Enables concurrent tracking of heart rate, ECG, and body composition. |
3nm Processor | High-efficiency computational engine. | Supports continuous background AI processing and long-term battery life for longitudinal studies. |
Dual-Frequency GPS | High-precision location tracking. | Allows for environmental context and mobility analysis in real-world population monitoring. |
325mAh / 445mAh Battery | Fast-charging, high-density power cells. | Ensures data continuity by minimizing downtime during the 24/7 monitoring cycle. |
3D Hall Sensor | Advanced magnetic field sensing (Classic model only). | Potential for specialized orientation and movement tracking in musculoskeletal research. |
The inclusion of a 3nm processor is particularly significant for clinical applications. This specialised silicon allows the device to run sophisticated AI algorithms locally, such as the Energy Score and Stress Monitoring, without depleting the battery, thus maintaining the high "on-wrist" time required for longitudinal research integrity.
Biometric Innovation and Digital Biomarker Discovery
The Galaxy Watch8 introduces several biometric measures that extend the scope of what can be monitored outside of a clinical setting. One such innovation is the Antioxidant Index, which measures carotenoid levels in the skin through light absorption in just five seconds. This provides a non-invasive proxy for cellular health and nutritional status, which can be a critical variable in cardiometabolic and oncology research. Traditionally, assessing oxidative stress required laboratory-based blood or tissue tests; the migration of this capability to a wearable device enables researchers to track the impact of lifestyle, diet, and therapeutic interventions in real-time.
Another critical research metric is the Vascular Load feature. By analyzing blood flow patterns via PPG during sleep, the watch can assess the strain on the vascular system and detect signs of arterial stiffness. This is a potent tool for preventative cardiovascular research, as it allows for the identification of risk factors before they escalate into clinical symptoms. The integration of these sensors with the Samsung Health app facilitates a "biohacking" approach for the consumer, but for the research sponsor, it provides a continuous stream of verified physiological data.
Regulatory Validation and FDA Clearances
The suitability of the Galaxy Watch8 for formal clinical trials is reinforced by its growing list of FDA clearances. The device has received clearance for its moderate-to-severe obstructive sleep apnea (OSA) assessment and its irregular heart rhythm notification (IHRN) feature, which detects signs suggestive of atrial fibrillation (AFib). These clearances establish "clinical-grade guardrails" that allow pharma sponsors to use watch-generated data as primary or secondary endpoints in regulated studies. The validation of these sensors across heart rate, blood oxygen (SpO2), and body composition measures further solidifies the device’s role as a robust research tool.
The Verily Pre Platform: An AI-Native Infrastructure for Precision Health
Verily’s Pre platform serves as the software and analytical foundation of the partnership, providing the necessary tools to harmonise, govern, and analyse the massive datasets generated by the Galaxy Watch8. Pre is described as an "AI-native" platform, meaning it was architected from the ground up to support the training, deployment, and monitoring of machine learning models in a healthcare context.
Modular Architecture and Data Solutions
The Pre platform is composed of several synergistic pillars that manage the entire lifecycle of research data. This modularity allows research sponsors to configure the platform based on the specific needs of their study, whether they are conducting a small pilot or a massive population health initiative.
Pre Platform Pillar | Functional Role | Key Capabilities |
Refinery | Curation and Harmonization Engine. | Ingests siloed, multi-source data and transforms it into a FHIR-native, AI-ready model. |
Exchange | Data and Model Marketplace. | Enables researchers to discover, share, and access unique multimodal datasets and AI agents. |
Workbench | Trusted Research Environment (TRE). | Provides cloud-transparent infrastructure (GPU/TPU) for collaborative analysis and model development. |
Verily Intelligence | AI/ML Service Layer. | Powers clinical labeling, protocol-to-workflow translation, and behavioral coaching agents. |
The platform's use of a FHIR-native (Fast Healthcare Interoperability Resources) data model is critical for ensuring that wearable data can be seamlessly integrated with electronic health records (EHR) and other clinical data sources. This standardisation is what allows Verily to "harmonise" data at the individual level, providing a truly holistic view of the participant's health journey.
AI Workflow Orchestration and Multimodal Data Processing
Verily Pre is designed to process both structured data (such as sensor logs and lab results) and unstructured data (such as PDF medical reports and clinical notes). A key demonstration of this capability is the platform’s "extensible enrichment system," which can extract numerical values from PDFs, standardise data using international medical codes like LOINC or SNOMED, and calculate derived measures such as Body Mass Index (BMI) using the standard formula $BMI = \frac{weight(kg)}{height(m)^2}$.
Furthermore, Verily’s workflow orchestration capabilities significantly reduce the administrative burden of clinical trials. The platform’s AI can ingest static PDF study protocols and translate them into dynamic, digital workflows for research sites. This automation allows sites to launch studies faster and ensures that data collection aligns strictly with the protocol, reducing errors and improving data quality.
The NVIDIA Collaboration and Computational Scaling
To support the intense computational demands of precision health AI, Verily has collaborated with NVIDIA to integrate the latter’s AI tech stack across the Pre platform. This includes the use of NVIDIA Blackwell-powered accelerated workflows and the integration of NVIDIA NeMo and CUDA-X for data science in the Workbench environment. This high-performance infrastructure enabled Verily researchers to develop the first multimodal foundation model using the NIH’s "All of Us" Research Program dataset, which integrates EHR and genomics data for deep health profiling. The "All of Us" Researcher Workbench, which supports over 19,000 researchers globally, is currently being powered by the next generation of the Pre platform.
Integration Mechanics: Bridging Hardware to Evidence through Viewpoint
The strategic partnership centers on making Galaxy Watch8 data accessible within Verily’s Viewpoint Evidence tool. This tool is the primary interface for research sponsors to interact with real-world data and manage participant cohorts.
The Lifelong Health Study and Participant Engagement
Viewpoint Evidence transforms research from a series of static snapshots into a "dynamic, ongoing conversation" with participants. This is facilitated by the Lifelong Health Study, a Verily-sponsored umbrella registry that builds a standing community of consented and engaged participants.
Through the partnership, Verily will actively recruit and engage Samsung Galaxy Watch users for participation in research studies. This integration ensures high-quality data capture and consistent device usage, as participants are recruited directly through the Verily Me consumer app. Verily Me serves as a central hub for users to manage their health records, receive personalized recommendations from clinicians, and opt-in to research opportunities. This "direct line" to participants allows sponsors to rapidly investigate safety signals, deploy new electronic Patient-Reported Outcome (ePRO) surveys, or prompt users for follow-up lab tests without the typical time and expense of launching a new study.
Data Harmonisation at the Individual Level
The true value of the partnership for pharma and government sponsors is the ability to harmonize continuous wearable data with a participant’s broader medical context. In the Viewpoint Evidence solution, sensor data from the Galaxy Watch is linked directly to:
Electronic Health Records (EHR): Providing a clinical baseline and historical context for the biometric signals.
Survey Responses: Capturing subjective patient experiences and life stressors.
Genomic and Third-Party Data: Offering a multi-dimensional view of the factors shaping long-term health.
This individual-level harmonization solves one of the most persistent issues in modern clinical trials: the inability to link "messy" real-world data with high-quality clinical endpoints. By providing an end-to-end system for deployment, collection, and analysis, Samsung and Verily "lower the friction" for adoption in regulated research.
Life Sciences and Pharmaceutical Applications: A New Era of Clinical Development
For the pharmaceutical industry, the Samsung-Verily collaboration offers a strategic pathway to improve the efficiency and success rates of drug development.
Digital Biomarker Discovery in Specialised Therapeutic Areas
The partnership builds on Verily’s extensive history in designing and verifying digital measures for therapeutic areas such as cardiometabolic, CNS (Central Nervous System), and respiratory diseases. A prime example is Verily’s development of advanced AI algorithms for Parkinson's disease, which established new standards for accuracy and reliability in tracking motor symptoms using wearable sensors.
With the Galaxy Watch8, sponsors can develop similar digital biomarkers for a wider range of conditions. In the "Cardiometabolic Cohort" managed through Viewpoint Evidence, researchers can unify lifestyle signals, body composition data, and heart rate variability to identify specific patient subpopulations. For example, AI models can be trained to identify patients at high risk of progressing from obesity to type 2 diabetes by analysing the interplay between "Vascular Load," activity levels, and clinical phenotypes extracted from EHR notes.
Decentralised Trials and Remote Monitoring
The integration of consumer-friendly hardware makes it significantly easier for participants to engage in and remain committed to clinical trials. Remote monitoring using the Galaxy Watch8 allows researchers to collect continuous health metrics—such as heart rate, sleep architecture, and physical activity—without requiring the participant to visit a clinical site. This capability is particularly valuable for tracking therapy adherence and disease progression in real-world settings.
The ability to access "raw device signals," such as raw photoplethysmography (PPG) waves and motion data from accelerometers and gyroscopes, allows pharma researchers to move beyond simple summary statistics. They can apply proprietary algorithms to this raw data to detect subtle changes in health, such as early indicators of heart failure or cognitive decline, which would be invisible to traditional episodic monitoring.
Research Application | Mechanism of Action | Business Impact |
Early Safety Signal Detection | Continuous monitoring of ECG and heart rhythm. | Reduces trial risk and improves patient safety. |
Deep Phenotyping | Linking wearable data to unstructured EHR notes via AI. | Improves patient stratification and trial design. |
Long-term Outcome Tracking | Longitudinal follow-up through the Lifelong Health Study. | Provides robust evidence for regulatory submissions and market access. |
Adherence Monitoring | Tracking activity and sleep patterns in real-world environments. | Clarifies the relationship between treatment and real-world outcomes. |
Government and Public Health: Enhancing Population Readiness and Research
The partnership also serves the critical needs of government agencies, particularly in the areas of public health monitoring and the management of human performance in high-stress environments.
Population Health Monitoring and Health Equity
Government researchers can utilise the Samsung-Verily solution to monitor the health of large-scale, diverse populations for up to several years. This is exemplified by the collaboration between Samsung, Tulane University, and Huma, which monitors thousands of participants to create biomarkers for the early detection of cardiovascular disease. By providing a scalable, consumer-grade tool for data collection, the partnership helps bridge the "digital divide" in health research, allowing agencies to reach underserved and rural communities that may lack access to traditional clinical research centres.
The use of AI-based mixed-effect random forest (MERF) models, as demonstrated in Samsung’s research with the MIT Media Lab, allows for the prediction of well-being indicators based on sleep and activity patterns. For public health agencies, this means the ability to assess the "resilience" of a population, its capacity to withstand and recover from stressors such as disease outbreaks or environmental disasters.
Defence and Mission-Ready Human Performance
Samsung’s "Health and Human Performance" solutions are specifically designed for defense, law enforcement, and first responders. The Galaxy Watch8, secured by the Samsung Knox platform, provides government agencies with a tool to enhance the readiness and recovery of personnel in demanding missions.
Key government use cases include:
Situational Awareness: Integrating biometric and GPS data with tactical software like ATAK on tactical tablets and smartphones.
Readiness Assessment: Analysing sleep, training exercises, and stress levels to maximise the effectiveness of military operators from basic training to active deployment.
Field Medical Care: Real-time vital monitoring through applications like BATDOK to assist medics in managing triage and CASEVAC (Casualty Evacuation) situations.
The watch's MIL-STD 810H certification ensures that it can operate reliably in temperatures ranging from -20°C to 50°C and survive the physical rigours of field operations.
Data Security, Privacy and Ethical AI Frameworks
Managing precision health data at scale requires a uncompromising approach to security and privacy. Both Samsung and Verily have implemented multi-layered frameworks to ensure compliance with global regulations and to maintain the trust of participants.
Samsung Knox and Device-Level Protection
At the device level, Samsung utilizes its Knox security platform to protect health data through strong encryption.Samsung’s approach to personal data protection involves continuous monitoring of global trends, the establishment of strict processing guidelines, and regular audits of its implementation. The company’s Privacy Legal Management System (PLMS) tracks compliance against regulations throughout the lifecycle of every product, from planning to discontinuation.
Samsung’s "Privacy Principles", Transparency, Security, and Choice, ensure that users are informed about what data is collected and have the means to manage their sharing preferences. This includes specific provisions for US state-level privacy rights and the EU-U.S. Data Privacy Framework (DPF).
Verily Pre Governance and Trusted Research Environments
Verily Pre was architected with a specific focus on the governance, auditability, and security required for healthcare data.The platform’s "Workbench" serves as a Trusted Research Environment (TRE), where researchers can co-analyze data within a secure cloud-transparent infrastructure. This environment allows for the enforcement of granular access policies without requiring complex coding, ensuring that only authorised personnel can interact with sensitive datasets.
Verily also adheres to a set of AI principles designed to ensure that its models are both useful and safe. This includes a rigorous "evaluation framework" for AI/ML models that combines automated testing with human-in-the-loop review.Every step of the model development lifecycle, from prototyping to continuous monitoring, is tracked and audited to ensure regulatory adherence and safety.
Behavioural Science and the "Activation" of Health Insights
A unique aspect of the Verily Pre platform is its ability to not just monitor health, but to "activate" insights through AI-driven coaching and behavior change strategies. This is critical for research sponsors who want to see the impact of interventions on long-term member engagement and outcomes.
Multi-Agent Workflows for Personalised Coaching
Verily Intelligence leverages a multi-agent AI architecture to support personalized health goals. This workflow is grounded in behavioural science principles and uses a comprehensive mapping of user barriers to evidence-based strategies.
Barrier Identification Agent: This specialised LLM agent probes for the root causes of a user's struggles, such as a lack of time, social pressure, or emotional eating. It uses motivational interviewing techniques to classify the user's situation into one of 28 predefined barrier concepts.
Strategy Execution Agent: Once a barrier is identified, this agent retrieves corresponding tactics and execution sequences from a predefined table. It then engages the user in a goal-oriented dialogue to equip them with the tools needed to overcome the barrier.
This proactive approach is integrated into the "Lightpath" and "Verily Me" solutions, enabling features like multimodal meal logging and personalised nutrition guidance based on image analysis. By combining these behavioural insights with the physical metrics from the Galaxy Watch8, such as sleep quality and activity levels, the platform can provide highly contextualised support that improves health outcomes over time.
Transitioning to Agentic AI and Seamless Connected Care
The partnership reflects a broader industry trend toward "Agentic AI"—where AI systems act as proactive companions rather than passive tools. For Samsung, this is embodied in the integration of upgraded Bixby, Google Gemini, and Perplexity into the Galaxy ecosystem, allowing users to coordinate tasks and adjust settings using natural language.
In the healthcare domain, this translates into "Connected Care." Samsung’s acquisition of Xealth in 2025 further strengthened this vision by allowing health systems to integrate digital health tools and patient data directly into physician workflows. This ensures that the insights generated by the Galaxy Watch8 and the Pre platform do not remain siloed but are instead delivered directly to the clinicians who manage patient care.
Future Outlook: Scaling Precision Health by 2030
The Samsung-Verily partnership is a cornerstone of both companies' long-term strategies to lead the AI-driven transformation of healthcare. Samsung’s initiative to transition its global manufacturing into "AI-Driven Factories" by 2030 parallels its goal to establish an autonomous, AI-driven production environment for health data.
As we look toward 2030, the integration of consumer wearables into the clinical research infrastructure will likely become the standard rather than the exception. The ability to generate "N-of-1" insights, personalised health models derived from an individual's unique data, will allow for a more predictive, preventive, and precise form of medicine. The collaborative infrastructure built by Samsung and Verily provides the necessary foundation for this future, offering a scalable, secure, and AI-native environment where research can keep pace with biomedical innovation.
By lowering the friction for pharma companies to use smartwatch data and providing government agencies with robust tools for population monitoring, the partnership is not only advancing research but also making precision health a reality for all. The continuous stream of evidence generated by the Galaxy Watch8 and refined by the Pre platform will ultimately lead to faster delivery of therapies, better patient outcomes, and a more comprehensive understanding of the complex factors that shape human health in the real world.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Comments